Q: I recently took profits and sold 3/4 of my position in Nobilis Health (NHC), as I did not feel comfortable with earnings "attributable to noncontrolling interests" being higher than those attributable too NHC (which resulted in a net loss for the quarter). Is this a concern? And how is this calculated?
I am thinking about re-investing the NHC cash into RX and/or GUD. Is there any reason why the market seems to be reacting negatively to RX's recent quarterly results (which actually beat consensus) or is this sell off just sector or valuation related? Also, I note that RX trades at a massive P/B ratio. Is this a concern? Is this a good entry point for RX?
And would you prefer GUD to RX or just buy both? I am fairly risk tolerant and my only other position in the health/biotech sector currently is PHM.
Thanks! Feel free to dock me a couple question credits for this doozy...
I am thinking about re-investing the NHC cash into RX and/or GUD. Is there any reason why the market seems to be reacting negatively to RX's recent quarterly results (which actually beat consensus) or is this sell off just sector or valuation related? Also, I note that RX trades at a massive P/B ratio. Is this a concern? Is this a good entry point for RX?
And would you prefer GUD to RX or just buy both? I am fairly risk tolerant and my only other position in the health/biotech sector currently is PHM.
Thanks! Feel free to dock me a couple question credits for this doozy...